Kurt R. Oettel

774 total citations
25 papers, 545 citations indexed

About

Kurt R. Oettel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kurt R. Oettel has authored 25 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Kurt R. Oettel's work include Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Kurt R. Oettel is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Kurt R. Oettel collaborates with scholars based in United States, Germany and Spain. Kurt R. Oettel's co-authors include R Erbes, Paul Fisch, M. Raffenberg, H. Lode, H. Mauch, Paul M. Sondel, Miroslav Malkovský, Jean E. Surfus, George Wilding and Mary Jane Staab and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and The Lancet Oncology.

In The Last Decade

Kurt R. Oettel

25 papers receiving 527 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kurt R. Oettel United States	10	200	150	133	95	73	25	545
Renée Baak-Pablo Netherlands	9	214 1.1×	180 1.2×	108 0.8×	113 1.2×	128 1.8×	16	691
Yukihiro Yano Japan	13	253 1.3×	98 0.7×	270 2.0×	79 0.8×	59 0.8×	48	546
Yoon Hwan Chang South Korea	15	118 0.6×	241 1.6×	83 0.6×	74 0.8×	99 1.4×	66	618
Kyoung Mee Kim South Korea	16	215 1.1×	202 1.3×	179 1.3×	58 0.6×	56 0.8×	40	653
Nathalie Letarte Canada	10	221 1.1×	137 0.9×	141 1.1×	52 0.5×	33 0.5×	26	477
Suhua Chen China	15	99 0.5×	168 1.1×	46 0.3×	126 1.3×	88 1.2×	53	694
Jota Watanabe Japan	12	134 0.7×	142 0.9×	59 0.4×	68 0.7×	63 0.9×	35	485
Jin Lu Tong China	12	240 1.2×	160 1.1×	68 0.5×	50 0.5×	92 1.3×	17	515
Jonathan M. Keller United States	11	117 0.6×	262 1.7×	63 0.5×	131 1.4×	54 0.7×	22	610
Kakil Ibrahim Rasul Qatar	9	192 1.0×	183 1.2×	116 0.9×	59 0.6×	33 0.5×	48	495

Countries citing papers authored by Kurt R. Oettel

Since Specialization

Citations

This map shows the geographic impact of Kurt R. Oettel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kurt R. Oettel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kurt R. Oettel more than expected).

Fields of papers citing papers by Kurt R. Oettel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kurt R. Oettel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kurt R. Oettel. The network helps show where Kurt R. Oettel may publish in the future.

Co-authorship network of co-authors of Kurt R. Oettel

This figure shows the co-authorship network connecting the top 25 collaborators of Kurt R. Oettel. A scholar is included among the top collaborators of Kurt R. Oettel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kurt R. Oettel. Kurt R. Oettel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lyman, Gary H., et al.. (2023). Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021. JCO Oncology Practice. 19(7). 516–522. 4 indexed citations

Sun, Zhuoxin, Bonnie Ky, Jenica Upshaw, et al.. (2022). A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181. Clinical Lung Cancer. 23(7). 547–560. 3 indexed citations

Oettel, Kurt R., et al.. (2022). Outcomes of a quality improvement project integrating an EHR (electronic health record) for improved adverse drug reaction (ADR) communication at an adult outpatient cancer infusion center.. Journal of Clinical Oncology. 40(28_suppl). 372–372. 1 indexed citations

Sun, Zhuoxin, Suresh S. Ramalingam, Heather A. Wakelee, et al.. (2021). Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).. Journal of Clinical Oncology. 39(15_suppl). TPS8584–TPS8584. 8 indexed citations

Mıkhael, Joseph, Judith Manola, Amylou C. Dueck, et al.. (2018). Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood Cancer Journal. 8(9). 86–86. 18 indexed citations

Smith, Angela, et al.. (2017). Are We on the Same Page? Patient and Provider Perceptions About Exercise in Cancer Care: A Focus Group Study. Journal of the National Comprehensive Cancer Network. 15(5). 588–594. 33 indexed citations

Herbst, Roy S., Mary W. Redman, Edward S. Kim, et al.. (2017). Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet Oncology. 19(1). 101–114. 60 indexed citations

Semrad, Thomas J., Mary W. Redman, Roy S. Herbst, et al.. (2016). Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 34(15_suppl). 9082–9082. 5 indexed citations

Traynor, Anne M., Tracey L. Weigel, Kurt R. Oettel, et al.. (2013). Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 81(1). 138–141. 57 indexed citations

10.

Hoang, Tien, Toby C. Campbell, Chong Zhang, et al.. (2013). Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Investigational New Drugs. 32(1). 195–199. 34 indexed citations

11.

LoConte, Noelle K., Kyle D. Holen, William R. Schelman, et al.. (2012). A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Investigational New Drugs. 31(4). 943–948. 9 indexed citations

12.

Oettel, Kurt R., et al.. (2010). Analysis of cancer clinical trials in the United States with comparison of National Institute of Health (NIH) and pharmaceutical industry (PHARMA)-sponsored studies.. Journal of Clinical Oncology. 28(15_suppl). 6084–6084. 1 indexed citations

13.

Attia, Steven, Anne M. Traynor, KyungMann Kim, et al.. (2008). Phase I/II Study of Vinorelbine and Exisulind as First-Line Treatment of Advanced Non-small Cell Lung Cancer in Patients at Least 70 Years Old: A Wisconsin Oncology Network Study. Journal of Thoracic Oncology. 3(9). 1018–1025. 2 indexed citations

14.

Hutson, Paul R., Kurt R. Oettel, Jeff Douglas, et al.. (2007). Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Cancer Chemotherapy and Pharmacology. 62(3). 373–377. 9 indexed citations

15.

Hoang, Tien, KyungMann Kim, Anne M. Traynor, et al.. (2006). Phase I/II Study of Gemcitabine and Exisulind as Second-Line Therapy in Patients with Advanced Non–small Cell Lung Cancer. Journal of Thoracic Oncology. 1(3). 218–225. 6 indexed citations

16.

Erbes, R, et al.. (2006). Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care. European Respiratory Journal. 27(6). 1223–1228. 88 indexed citations

17.

Oettel, Kurt R., Lynn Van Ummersen, Kyung Mann Kim, et al.. (2005). Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma. Investigational New Drugs. 24(3). 255–260. 9 indexed citations

18.

Liu, Glenn, Kurt R. Oettel, Howard H. Bailey, et al.. (2003). Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Investigational New Drugs. 21(3). 367–372. 45 indexed citations

19.

Liu, Glenn, Kurt R. Oettel, Gregory H. Ripple, et al.. (2002). Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.. PubMed. 8(9). 2820–7. 57 indexed citations

20.

Sosman, Jeffrey A., Kurt R. Oettel, Jacquelyn A. Hank, Paul Fisch, & Paul M. Sondel. (1989). SPECIFIC RECOGNITION OF HUMAN LEUKEMIC CELLS BY ALLOGENEIC T CELL LINES. Transplantation. 48(3). 486–494. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact